While a €100 billion package is a serious commitment, Europe's largest energy-intensive industries will require far more than ...
NewAmsterdam Pharma (NAMS) outlook: obicetrapib could cut cardiovascular risk beyond LDL-C. Key catalysts into 2026–27; ...
Greenlight Capital's 13F portfolio rose from $2.85B to $3.19B in Q1 2026, outperforming the S&P 500 with a 6.5% return vs. -4 ...
ETB's 8.15% distribution yield is attractive and tax-efficient, making it suitable for taxable accounts. Read why ETB is ...
Compare 12%-yielding tech lenders HTGC vs. TRIN at 1.3x NAV—pros, cons, and which fits your portfolio. Click to read more.
Unlike traditional mutual funds or ETFs, secondary market CEFs routinely decouple from true book values. Here's what you need ...
Gold Royalty (GROY) shifts to cash-flow compounding as acquisitions boost near-term revenue and long-term growth.
Neocloud stocks after the sell-off: see why analysts favor Applied Digital (APLD) and Nebius (NBIS). Read more here.
COPX is 23% below highs despite strong copper. Explore why miners lag, key risks (China, inventories) and electrification ...
Axon Q1 beats and raises 2025 revenue growth to 30–32%, but weak FCF and cash conversion risks persist. Click to read more ...
Healthcare systems are facing rising operating pressure, thinner margins, and a harder question about how to manage liquidity ...
Isabella Bank missed Q2 2026 EPS, marking the third consecutive earnings miss and highlighting ongoing growth challenges.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results